Combining therapies, through cooperative inhibition or stimulation of multiple targets, offer a promising approach for effective treatment, and different drugs have been combined with TRAs in attempts to increase the efficacy of the drugs.21–25 Approximately 50% of all melanoma patients harbor mutated BRAF causing constitutive active MAPK/ERK pathway. The gene discussed is BRAF; the disease is melanoma.